• Strong financial and operational performance, with record cash receipts and revenue growth
• Flagship launch of Clinico-branded Audeara healthy hearing earbuds in Taiwan and $0.57m purchase order
• $0.9m purchase order from global music instrument manufacturer Avedis Zildjian

Audeara Ltd (ASX: AUA) reported a strong Q3 FY25, with record cash receipts of $1.64m, up 46% on the prior comparative period, and year-to-date cash receipts now totalling $3.9m, an 11% increase on the full FY24. Quarterly unaudited revenue reached $1.26m, a 230% rise on the previous quarter and 113% year-on-year. The company also reduced net operating cash outflows by 87% to $73,000 compared to the previous quarter. Key highlights included the flagship launch of Clinico-branded Audeara healthy hearing earbuds in Taiwan, alongside a $0.57m maiden purchase order, and a $0.9m purchase order from global music instrument manufacturer Avedis Zildjian, marking the second phase of mass production. Audeara also executed a reseller agreement with George & Matilda Eyecare, a leading independent optical network in Australia, to offer its range of tailored audio solutions. The company continued to advance its Auracast-enabled technology, with permanent installations at the University of Queensland and ongoing discussions with other mass retail outlets, entertainment venues, and academic institutions. Looking ahead, Audeara is focused on finalizing the technology platform to launch its hearing aid technology licensing business in collaboration with Eastech into key international markets, as well as engaging with global brands to secure new partnerships across its technology licensing offerings.

Audeara expects to continue delivering pleasing operational and financial performance in the current quarter and beyond, with initial payments received post-quarter end from a large audiology clinic, the pending roll out through George & Matilda Eyecare, and a number of other AUA Technology related developments pending.

In the current quarter, Audeara is actively pursuing initiatives that are expected to deliver near-term outcomes, including finalizing the technology platform required to launch its hearing aid technology licensing business in collaboration with Eastech into key international markets, and actively engaging with global brands to secure new partnerships across the broader suite of Audeara's technology licensing offerings, positioning the company for further revenue growth.